854472-72-3Relevant academic research and scientific papers
Imidazo ring PAR4 antagonist and medical applications thereof
-
Paragraph 0457; 0459; 0461, (2020/01/12)
The invention relates to an imidazo ring compound represented by formula (I) or formula (II), or a pharmaceutically acceptable salt or ester or solvate thereof. The compound disclosed by the inventioncan be used for preparing medicines for preventing or treating thromboembolic diseases.
Synthesis and biological evaluation of potent bisubstrate inhibitors of the enzyme catechol O-methyltransferase (COMT) lacking a nitro group
Paulini, Ralph,Lerner, Christian,Diederich, Francois,Jakob-Roetne, Roland,Zuercher, Gerhard,Borroni, Edilio
, p. 1856 - 1887 (2007/10/03)
Inhibition of the enzyme catechol O-methyltransferase (COMT) represents a viable strategy for regulation of the catabolism of catecholamine neurotransmitters or their precursors, and is of considerable interest in the therapy of Parkinson's, disease. Here
New COMT inhibitors for the treatment of depression and impaired cognition
-
Page/Page column 33, (2010/02/12)
The present invention relates to compounds of formula I wherein R1 is as defined in the specification and to esters thereof which are hydrolyzable under physiological conditions and to the pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of COMT and, thus, are useful for the treatment of diseases for which COMT inhibition is beneficial. The invention further relates to the treatment, control, or prevention of diseases such as depression, schizophrenia, Parkinson's disease, and to improve cognition.
